ClinicalTrials.gg
Not yet recruitingNCT06763692Updated Feb 17, 2026

Low Intensity Focused Ultrasound for Parkinson's Disease

An interventional study of LIFU Neuromodulation in Parkinson Disease, sponsored by Ali Rezai. Not yet recruiting. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Ali Rezai · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
45 Years to 80 Years
Sex
All
01

Study summary

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with parkinson's Disease

Read the detailed description

The primary objective is to evaluate the safety, feasibility and tolerability of LIFU as an adjunct neuromodulatory treatment for Parkinson's Disease

02

Conditions studied

  • Parkinson Disease

Browse trials for

03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 15 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Ali Rezai is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-pregnant females aged 45 - 80 years at time of enrollment.
  • Able and willing to give .
  • Diagnosis of probable idiopathic Parkinson's disease by United Kingdom Parkinson's Disease
  • Clinical diagnosis based on the Level II Movement Disorder Criteria and an FAQ less than or equal to 9.
  • If on medication for the treatment of PD, or other medications for any other underlying medical conditions, must be on a stable dose for ≥4 weeks prior to Screening.
  • Willing to not receive DBS or any other approved or experimental surgical or medical therapy for PD during the study period.
  • Males and non-pregnant females aged 45 - 80 years at time of enrollment.
  • Able and willing to give informed consent.
  • Diagnosis of probable idiopathic Parkinson's disease by United Kingdom Parkinson's Disease
  • Clinical diagnosis based on the Level II Movement Disorder Criteria and an FAQ less than or equal to 9.
  • If on medication for the treatment of PD, or other medications for any other underlying medical conditions, must be on a stable dose for ≥4 weeks prior to Screening.
  • Willing to not receive DBS or any other approved or experimental surgical or medical therapy for PD during the study period.

Exclusion criteria

Exclusion Criteria:

  • Unable to undergo MR-imaging because of non-MR compatible implants (e.g., pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent make-up or small metal fragments in the eye that welders and other metal workers may have), or if candidates are uncomfortable in small spaces (have claustrophobia).
  • Active or chronic infection/inflammation
  • Acute or chronic hemorrhages, specifically any lobar microbleeds with GRE and no siderosis or macro hemorrhages
  • Tumor/space occupying lesion anywhere in the brain
  • Participants who are unable or unwilling to lay flat and tolerate the required prolonged stationary position during treatment (approximately 2-3 hours).
  • Participants with more than 30% of the skull area traversed by the sonication pathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp, or implanted objects in the skull or the brain.
  • Participants with known unstable cardiac status or uncontrolled hypertension
  • History of any neurological disorder or procedure (e.g., brain surgery for Parkinson's disease, tumors, uncontrolled epilepsy, or any others deemed clinically significant by the investigator).
  • Participant who has had deep brain stimulation or a prior stereotactic ablation of the basal ganglia, or thalamus.
  • Currently participating in another clinical investigation with an active treatment arm or participated in any experimental therapy (drug or biologic or device) within 3 months prior to Screening.
  • Use of any medications that, in the opinion of the Investigator, may contribute to cognitive impairment, put the participant at higher risk for AEs, or impair the participant's ability to perform cognitive testing or complete study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    LIFU Neuromodulation

    Device: LIFU Neuromodulation

Interventions

  • DeviceLIFU Neuromodulation

    Subjects will undergo a single LIFU of the target brain region

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events

    All adverse events that are related to LIFU will be assessed

    Time frame: baseline and day 7, 30 and 90 after study procedure

Secondary outcomes

  1. Effect of LIFU on visuospatial function,

    prosaccade (PST) and antisaccade (AST) task

    Time frame: baseline and day 7, 30 and 90 after study procedure

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 3 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 8, 2025
StartEst.
Dec 1, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06763692
Lead sponsor
Ali Rezai
Responsible party
Ali Rezai (Director RNI, West Virginia University) — Sponsor-investigator
First posted
Jan 8, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Feb 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion